Reports
Sale
Asia Pacific Biosimilar Insulin Glargine and Lispro Market Size, Share, Growth, Trends, Forecast: By Type: Branded Drug, Biosimilar Drug; By Indications: Type 1 Diabetes, Type 2 Diabetes; By Distribution Channel: Hospitals, Commercial, Store-Based, Others; Market Dynamics: SWOT Analysis; Regional Analysis; Supplier Landscape; 2024-2032
Asia Pacific Biosimilar Insulin Glargine and Lispro Market Outlook
The growth of the Asia Pacific biosimilar insulin glargine and lispro market size is driven by the growth in the global biosimilar insulin glargine and lispro market, which attained a value of USD 2,131.47 million in 2023. The global market is anticipated to grow at a CAGR of 14.3% during the forecast period of 2024-2032, likely to attain a value of USD 7,097.32 million by 2032.
Biosimilar Insulin Glargine and Lispro: Introduction
Biosimilar insulin is assumed as a potential alternate to expensive therapies. It is an injectable insulin which starts acting within fifteen minutes of injection and stays active till two to four hours after the injection. Due to the involvement of biosimilar insulin in healthcare, the market for biosimilar insulin glargine and lispro has gained significant traction over the last few years.
On the other hand, insulin lispro is a hormone which is used to lower the blood sugar levels. Insulin lispro acts fast, within fifteen minutes after the use. It takes at least two hours for it to strike the highest point and then it remains active for another two to four hours. This insulin is used in people who are suffering from diabetes mellitus including children. There are two type of insulin lispro that are being used in the treatment of type II diabetes in adults, type I diabetes in adults, and amongst children that are 3 years and older in age.
Asia Pacific Biosimilar Insulin Glargine and Lispro Market Analysis
The growth of the market is primarily driven by the rising prevalence of diabetes and other hormonal imbalance related disorders. Other key trends justifying the Asia Pacific biosimilar insulin glargine and lispro market growth include the rising healthcare sector, rising emphasis on better healthcare facilities, increasing prevalence of diabetes among the geriatric population. With the breakthrough advancement of technology and facilities in the healthcare sector, the market is anticipated to witness higher demand in the coming years.
Asia Pacific Biosimilar Insulin Glargine and Lispro Market Segmentations
Market Breakup by Type
- Branded Drug
- Biosimilar Drug
Market Breakup by Indications
- Type 1 Diabetes
- Type 2 Diabetes
Market Breakup by Distribution Channel
- Hospitals
- Commercial
- Store-Based
- Others
Market Breakup by Region
- China
- Japan
- India
- ASEAN
- Australia
- Others
Asia Pacific Biosimilar Insulin Glargine and Lispro Market Overview
The growth of the market is primarily being driven by the rising cases of diabetes across the Asia Pacific region, especially in India. Diabetes is a chronic autoimmune disease which can be a life-threatening disease if not taken care of. With diabetes, the production of insulin in the body almost or completely stops. Hence, it is important to fulfill the requirement of insulin externally. Due to the rising prevalence of diabetes and the rising number of fatalities across the region, the biosimilar insulin glargine and lispro market demand is constantly rising.
The other factor driving the market growth is the increasing geriatric population and unhealthy lifestyle including unhealthy eating habits, absence of active lifestyle, among others. According to the market segment by type, the market is divided into two categories which are branded and biosimilar drugs. Additionally, China is the leading country where the demand of the biosimilar insulin glargine and lispro is the highest in Asia Pacific.
Asia Pacific Biosimilar Insulin Glargine and Lispro Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Sanofi S.A.
- Biocon Limited
- Novo Nordisk A/S
- Wockhardt Ltd.
- Eli Lily and Company
- Julphar Diabetes LLC
- SAJA Pharmaceuticals
- Gan & Lee Pharmaceutical Ltd.
- Cipla Limited
- Merck & Co.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Indications |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Asia Pacific Biosimilar Insulin Glargine and Lispro Market Overview
3.1 Asia Pacific Biosimilar Insulin Glargine and Lispro Market Historical Value (2017-2023)
3.2 Asia Pacific Biosimilar Insulin Glargine and Lispro Market Forecast Value (2024-2032)
4 Asia Pacific Biosimilar Insulin Glargine and Lispro Market Landscape
4.1 Asia Pacific Biosimilar Insulin Glargine and Lispro Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Asia Pacific Biosimilar Insulin Glargine and Lispro Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Indications
5 Asia Pacific Biosimilar Insulin Glargine and Lispro Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Asia Pacific Biosimilar Insulin Glargine and Lispro Market Segmentation
6.1 Asia Pacific Biosimilar Insulin Glargine and Lispro Market by Type
6.1.1 Market Overview
6.1.2 Branded Drug
6.1.3 Biosimilar Drug
6.2 Asia Pacific Biosimilar Insulin Glargine and Lispro Market by Indications
6.2.1 Market Overview
6.2.2 Type 1 Diabetes
6.2.3 Type 2 Diabetes
6.3 Asia Pacific Biosimilar Insulin Glargine and Lispro Market by Distribution Channel
6.3.1 Market Overview
6.3.2 Hospitals
6.3.3 Commercial
6.3.4 Store-Based
6.3.5 Others
6.4 Asia Pacific Biosimilar Insulin Glargine and Lispro Market by Country
6.4.1 Market Overview
6.4.2 China
6.4.3 Japan
6.4.4 India
6.4.5 ASEAN
6.4.6 Australia
6.4.7 Others
7 Patent Analysis
7.1 Analysis by Type of Patent
7.2 Analysis by Publication year
7.3 Analysis by Issuing Authority
7.4 Analysis by Patent Age
7.5 Analysis by CPC Analysis
7.6 Analysis by Patent Valuation
7.7 Analysis by Key Players
8 Grants Analysis
8.1 Analysis by year
8.2 Analysis by Amount Awarded
8.3 Analysis by Issuing Authority
8.4 Analysis by Grant Application
8.5 Analysis by Funding Institute
8.6 Analysis by NIH Departments
8.7 Analysis by Recipient Organization
9 Funding Analysis
9.1 Analysis by Funding Instances
9.2 Analysis by Type of Funding
9.3 Analysis by Funding Amount
9.4 Analysis by Leading Players
9.5 Analysis by Leading Investors
9.6 Analysis by Geography
10 Partnership and Collaborations Analysis
10.1 Analysis by Partnership Instances
10.2 Analysis by Type of Partnership
10.3 Analysis by Leading Players
10.4 Analysis by Geography
11 Regulatory Framework
11.1 Regulatory Overview
11.1.1 US FDA
11.1.2 EU EMA
11.1.3 INDIA CDSCO
11.1.4 JAPAN PMDA
11.1.5 Others
12 Supplier Landscape
12.1 Sanofi S.A.
12.1.1 Financial Analysis
12.1.2 Product Portfolio
12.1.3 Demographic Reach and Achievements
12.1.4 Mergers and Acquisition
12.1.5 Certifications
12.2 Biocon Limited
12.2.1 Financial Analysis
12.2.2 Product Portfolio
12.2.3 Demographic Reach and Achievements
12.2.4 Mergers and Acquisition
12.2.5 Certifications
12.3 Novo Nordisk A/S
12.3.1 Financial Analysis
12.3.2 Product Portfolio
12.3.3 Demographic Reach and Achievements
12.3.4 Mergers and Acquisition
12.3.5 Certifications
12.4 Wockhardt Ltd.
12.4.1 Financial Analysis
12.4.2 Product Portfolio
12.4.3 Demographic Reach and Achievements
12.4.4 Mergers and Acquisition
12.4.5 Certifications
12.5 Eli Lily and Company
12.5.1 Financial Analysis
12.5.2 Product Portfolio
12.5.3 Demographic Reach and Achievements
12.5.4 Mergers and Acquisition
12.5.5 Certifications
12.6 Julphar Diabetes LLC
12.6.1 Financial Analysis
12.6.2 Product Portfolio
12.6.3 Demographic Reach and Achievements
12.6.4 Mergers and Acquisition
12.6.5 Certifications
12.7 SAJA Pharmaceuticals
12.7.1 Financial Analysis
12.7.2 Product Portfolio
12.7.3 Demographic Reach and Achievements
12.7.4 Mergers and Acquisition
12.7.5 Certifications
12.8 Gan & Lee Pharmaceutical Ltd.
12.8.1 Financial Analysis
12.8.2 Product Portfolio
12.8.3 Demographic Reach and Achievements
12.8.4 Mergers and Acquisition
12.8.5 Certifications
12.9 Cipla Limited
12.9.1 Financial Analysis
12.9.2 Product Portfolio
12.9.3 Demographic Reach and Achievements
12.9.4 Mergers and Acquisition
12.9.5 Certifications
12.10 Merck & Co.
12.10.1 Financial Analysis
12.10.2 Product Portfolio
12.10.3 Demographic Reach and Achievements
12.10.4 Mergers and Acquisition
12.10.5 Certifications
13 Asia Pacific Biosimilar Insulin Glargine and Lispro Market - Distribution Model (Additional Insight)
13.1 Overview
13.2 Potential Distributors
13.3 Key Parameters for Distribution Partner Assessment
14 Key Opinion Leaders (KOL) Insights (Additional Insight)
15 Company Competitiveness Analysis (Additional Insight)
15.1 Very Small Companies
15.2 Small Companies
15.3 Mid-Sized Companies
15.4 Large Companies
15.5 Very Large Companies
16 Payment Methods (Additional Insight)
16.1 Government Funded
16.2 Private Insurance
16.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The growth of the Asia Pacific biosimilar insulin glargine and lispro market is driven by the growth in the global biosimilar insulin glargine and lispro market, which attained a value of USD 2,131.47 million in 2023.
The growth of the Asia Pacific biosimilar insulin glargine and lispro market is anticipated to be driven by the rising global market. The global market is anticipated to grow at a CAGR of 14.3% during the forecast period of 2024-2032, likely to attain a value of USD 7,097.32 million by 2032.
The growth of the market is driven by various factors including rising population, growing healthcare sector, rising prevalence of diabetes across the region, and the rising disposable incomes.
The major regions of the market include China, Japan, India, ASEAN, Australia, among others. Amongst these regions, China accounts for the largest market share.
The different types available in the market can be categorized into branded drug and biosimilar drug.
The different indications in the market are type 1 diabetes and type 2 diabetes.
The different distribution channels in the market are hospitals, commercial, and store-based, among others.
The rapid technological advancements in the market and understanding the cost-effective nature of the treatment are among the key trends in the market.
Key players involved in the market are Sanofi S.A., Biocon Limited, Novo Nordisk A/S, Wockhardt Ltd., Eli Lily and Company, Julphar Diabetes LLC, SAJA Pharmaceuticals, Gan & Lee Pharmaceutical Ltd., Merck & Co., and Cipla Limited.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2639
$2399
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 4399
$3999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 5829
$5299
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 6929
$6299
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER